Efimosfermin alfa (BOS-580) once per month in people with metabolic dysfunction-associated steatohepatitis with F2 or F3 fibrosis: results from a 24-week, randomised, double-blind, placebo-controlled, phase 2 trial

The Lancet 2026

View at publisher

Authors: Mazen Noureddin, Kris V Kowdley, Tatjana Odrljin, Gerard Bain, Jeff Zhao, Brenda I. Jeglinski, Margaret James Koziel, Rohit Loomba

DOI: 10.1016/s0140-6736(25)02276-7

Cited by: 9

References: 25

Fields of Study & Subjects

Liver Disease Diagnosis and Treatment Folate and B Vitamins Research Nutrition and Health in Aging

References 25